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Abstract
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma
and multiple myeloma. These therapies targeting disease-speciﬁc antigens, such as CD19 in lymphoma and B cell
maturation antigen in multiple myeloma, are efﬁcacious and well-tolerated compared with conventional chemotherapies. Unfortunately, their potential remains unrealized in acute myeloid leukemia (AML). This is because most
targetable antigens on AML cells are also expressed on healthy myeloid hematopoietic stem cells (HSC). Therefore,
targeting them results in severe myeloablative effects and pancytopenia. Several strategies have been devised to overcome this barrier, including identifying AML-speciﬁc antigens, limiting CAR-T cell persistence to prevent prolonged
myeloablation, and creating AML-speciﬁc antigens through manipulating HSCs prior to allogenic transplant. In this
review, we discuss these strategies and the ongoing clinical trials on adoptive cellular therapies in AML, limiting our
focus to chimeric antigen receptor-T cells (CAR-T) and chimeric antigen receptor-natural killer cells (CAR-NK).
Keywords: Acute myeloid leukemia, Chimeric antigen receptor, Cellular therapy, Adoptive therapy, CAR-T cells, CARNK cells

1. Introduction

A

doptive
cellular
therapy,
particularly
chimeric antigen receptor-T cells (CAR-T),
has revolutionized the management of hematologic
malignancies,
particularly
lymphoma,
acute
lymphoblastic leukemia (ALL), and multiple
myeloma (MM) [1,2]. Currently, six CAR-T products
are approved by the United States Food and Drug
Administration (FDA). These include CD-19directed axicabtagene ciloleucel, tisagenlecleucel,
and lisocabtagene maraleucel for relapsed refractory B cell non-Hodgkin's lymphoma [3e5], CD19-directed brexucabtagene autoleucel for mantle
cell lymphoma and adults with ALL [6], and B cell
maturation antigen (BCMA)-directed idecabtagene
vicleucel and ciltacabtagene autoleucel for relapsed/

refractory MM [7,8]. The success and promise of
CAR-T cell therapy have not been realized in acute
myeloid leukemia (AML), and currently, there are
no FDA-approved products for the disease.
Apart from CAR-T, adoptive cellular therapy has
expanded over the years to include several other
constructs that are currently being evaluated in
hematologic and solid malignancies (for example,
chimeric antigen receptor-natural killer cells [CARNK], tumor-inﬁltrating lymphocyte therapy [TIL],
tumor-activated T cells and T cell receptor [TCR])
[9]. CAR-NK cells may have potential advantages
over CAR-T cell therapy, including reduced toxicity,
reduced incidence of cytokine release syndrome
(CRS), neurotoxicity, low risk of graft-versus-host
disease in the allogenic setting, and possible “offthe-shelf” use [10]. While there are no FDA-
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approved CAR-NK therapies, several products are
being investigated in hematologic malignancies,
including AML [11].
We aim to review the current scope of adoptive
cellular therapy in AML, including the challenges in
their development and clinical trials evaluating their
use. For the scope of this article, we will be limiting
our focus to CAR-T and CAR-NK cell therapies.

2. Approaches to adoptive T cell therapy in
AML
In the context of AML, an ideal target for adoptive
cell therapy is expressed on the blast cell surface,
including leukemia stem cells, and is absent from
normal hematopoietic cells. It has been challenging
to identify such targets in AML since the commonly
expressed antigens are also present on normal hematopoietic stem cells (HSCs), including CD33,
CD34, and CD123 [12]. Hence, CAR-T/NK cells targeting these antigens are unable to differentiate between cancer and normal cells. Studies have shown
prolonged severe myelosuppression and transfusion
dependence with their use. [13e15], resulting in
potentially fatal bleeding, neutropenia, and opportunistic infections. Several approaches to address
these challenges are undergoing investigation.
2.1. Identifying appropriate AML-speciﬁc antigens
When compared with solid tumors, AML has one
of the lowest mutational burdens. Hence, it has
lesser neoantigens that could act as targets for
adoptive T cell therapy. In addition, given the heterogeneous nature of the disease, there is no single
protein target expressed by all AML subtypes [16].
Several methods have attempted to identify
AML-speciﬁc antigens and neoantigens to overcome the challenges associated with prolonged
myeloablation. Currently, several AML-speciﬁc
targets are being utilized in clinical trials (Table 1).

2.1.1. Cell-surface targets
CD7, a transmembrane protein expressed in
about 30% of adult AML patients, is typically seen in
activated T cells but is absent on normal myeloid
and erythroid cells. CD7-deﬁcient mice retain
normal T cell function, making its function possibly
redundant. When present in AML, it is associated
with chemotherapy resistance and a more aggressive disease course. Preclinical data have shown that
CD7 CAR-T cells provide protection against severe
leukemia in xenograft models, and clinical trials
using CD7 CAR-T products are in progress [17,18].
CD33 is sialic acid-binding immunoglobulin primarily expressed in cells of the myeloid lineage,
including myeloid progenitor cells, and in around
85e90% of AML cases, making it a potential target
for CAR-T cell therapy. A phase I trial to assess the
safety and efﬁcacy of CAR-T-33 cells showed
marked disease regression in a 41-year-old with
relapsed/refractory (r/r) AML but with early disease
relapse [19].Another single-center phase I clinical
trial assessing the safety and feasibility of CD33
CAR-T cells in r/r AML enrolled ten patients, three
of whom eventually received the CAR-T cells. Disease response was not achieved with CD33 CAR-T
in any of the three patients. Cytokine release syndrome (CRS), immune effector cell-associated
neurotoxicity syndrome (ICANS), tumor lysis syndrome, respiratory distress syndrome, and septic
shock were some of the adverse effects noted with
CD33 CAR-T in the trial [20]. Fig. 2 describes some
ongoing clinical trials using CD33 CAR-T cells.
CD123, also called IL-3 receptor subunit alpha, is
seen in 70e80% of patients with AML and is primarily expressed on myeloid lineage cells. AntiCD123 CAR-T cells can successfully ablate leukemic
blasts in preclinical studies. The ﬁrst-in-human
clinical trial of CD123 CAR-T cell therapy enrolled
six patients with refractory AML following alloHSCT therapy. Three out of six patients had complete remission, and no myeloablative effects were

Table 1. Investigational AML-speciﬁc target antigens for CAR-T/NK cell therapy.
Antigen

Cellular location
of expression

Expression
in AML

Expressed in HSCs

Expression in other
non-leukemic
healthy cells

Use in clinical trials

CD7 [17,18]

Transmembrane

Yes, 30%
of cases

Mature T cells/NK
cells

CAR-T (NCT04762485)

CD44v6 [24]

Surface

Yes, 60%
of cases

Yes (T cell precursors);
Absent in erythroid or
myeloid cells
No

CAR-T (NCT04097301)

FLT3 [26,27]

Transmembrane

Yes

Yes

NKG2D
ligand [29,30]

Surface

Yes

No

Keratinocytes,
monocytes, activated T cells
Dendritic cells, NK
cells
No

CAR-T (NCT05023707)
CAR-T [30]
CAR-NK (NCT05247957)
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observed [21]. Currently, several clinical trials with
CAR-T targeting CD123 are ongoing (Fig. 2).
CLL-1, also known as C-type-lectin-like molecule
1, is expressed on >80% of AML blasts. It has
become a popular target for CAR cells as it is
notably absent on granulocyte progenitors and nonhematologic tissues. Several preclinical studies have
established the anti-leukemic activity of CLL-1directed CARs without destroying normal HSCs. A
case report by Zhang et al. showed morphological,
immunophenotypic, and molecular complete
remission for over ten months in a patient with
AML treated with anti-CLL1 CAR-T therapy [22].
Moreover, in a phase I/II anti-CLL1 CAR-T cell
therapy trial that enrolled four pediatric patients
with r/r AML, three patients achieved complete
remission with only low-grade adverse events [23].
Several trials assessing the utility of anti-CLL-1 CAR
clinical trials are ongoing (Fig. 2).
Another potential target is CD44v6, which is present in up to 60% of AML cases. CD44 is an adhesive
receptor expressed on multiple tissue types, but its
splice variant CD44v6 is relatively tumor restricted.
Casucci et al. showed that T cells targeting CD44v6
with a newly designed CAR-T cell therapy mediated
a potent anti-leukemia effect without harming HSCs
in xenograft mouse models [24]. A clinical trial using
CAR-T cells targeting CD44v6 in relapsed refractory
AML and MM was initiated in Italy but terminated
early, without enrollment of any AML patients
(NCT04097301).
Fms-related tyrosine kinase 3 (FLT3) is a gene that
encodes a transmembrane tyrosine kinase receptor,
which helps in hematopoiesis and regulates the
survival of normal HSCs [25]. FLT3-ITD and FLT3TKD mutations are associated with poor prognosis
in AML. Agents like giltertinib, quizartinib, and
midostaurin are FDA approved for FLT3 mutated
AML, and hence exploring the role of CAR-T cells in
targeting FLT3 is of interest. Preclinical data of FLT3
CAR-T cells against leukemic cell lines has been
promising, and their utility in the real world is being
studied in clinical trials [26,27].
The Natural Killer Group 2 member D (NKG2D)
ligands are another set of novel therapeutic targets.
Their expression is upregulated in conditions of
cellular stress, such as DNA damage, inﬂammation,
and malignant transformation. As a result, multiple
tumor types, including AML, express NKG2D ligands, whereas their expression is low in healthy
cells, making them a good target for anti-tumor
therapies [28]. NKG2D receptor, on the other hand,
is expressed selectively on healthy NK cells, CD8þ T
cells, subsets of CD4þ T cells, and gd T cells [29]. In
its native form, the NKG2D receptor recognizes its
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ligand on tumor cells and provides a costimulatory
signal to T cells. However, it relies on antigen
recognition via the T cell receptor (TCR) to deliver
the primary activating signal. In contrast, NKG2D
ligand recognition through the NKG2D-CAR-T cells
mediates primary T cell activation. A phase 1 clinical
trial by Baumeister et al. in patients with AML/
Myelodysplastic
Syndrome
(MDS)/Multiple
Myeloma (MM) using NKG2D CAR-T cells without
lymphodepleting chemotherapy found limited
expansion and persistence of CAR-T cells but did
detect functional activity. No objective anti-tumor
responses were seen with a single dose; however, no
dose-limiting toxicity occurred [30]. A preclinical
study by Driouk et al. demonstrated increased
NKG2D-ligand expression in AML cells after
exposure to histone deacetylase (HDAC) inhibitors.
This effect was not noted on healthy cell lines.
Furthermore, this HDAC-mediated upregulation in
NKG2D-ligand expression translated to improved
anti-leukemic efﬁcacy of NKG2D CAR-T cells in
vitro, thus providing a rationale for combining
HDAC inhibitors with NKG2D-CAR-T cell therapy
in the treatment of AML [31]. Efforts to utilize
NKG2D ligand as a target by CAR-T cells are
ongoing in multiple clinical trials (Fig. 2).
2.1.2. Intracellular targets
A comprehensive analysis of the Cancer Genome
Atlas Research Network identiﬁed several immunogenic AML-associated neoantigens, such as mutations of enzymes IDH1, IDH2, and NPM1 [32].
Proteins associated with these mutations are
expressed intracellularly and inaccessible to conventional CAR-T/NK cell therapies typically
directed towards surface antigens. To overcome this
problem, an innovative approach of gene-transduced tumor-speciﬁc T cell receptor (TCR) T cells is
being studied in multiple clinical trials. In contrast
to CAR-T cells that target naturally occurring antigens, TCR T cells are engineered to express receptors speciﬁc to certain tumor-associated antigens
formed from a complex of a tumor peptide and an
MHC molecule. For instance, a study by Chapuis
et al. investigated the prophylactic use of TCR T
cells directed against Wilms tumor 1 (WT1) antigen
as a novel mechanism to reduce relapse risk after
hematopoietic cell transplantation in AML patients.
Twelve patients received WT-1-directed T cells and
reported 100% relapse-free survival at the median of
44 months, which was signiﬁcantly higher
compared with the 54% rate in the comparative
group [33]. Several preclinical studies have suggested the possible role of shared neoantigens
(mutated antigens common amongst different
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cancer patients but not expressed in the normal
genome), such as Nucleophosmin1 (NPM1) mutations, core-binding factor-b, and myosin heavy
chain 11 (CBFB-MYH11), in TCR-based immunotherapy of AML [34,35].
Another target for TCR-based immunotherapy in
AML patients who experience disease relapse post
allogeneic hematopoietic cell transplantation is the
minor histocompatibility (H) antigen HA1, which is
hematopoietic restricted and expressed in leukemia
cells [36]. The rationale behind this approach is that
TCR-transduced lymphocytes will target HA1 present on leukemic cells but not donor HSCs or nonhematopoietic host cells, thus having a selective
anti-leukemia effect without causing graft-vs-host
disease. A phase 1 trial using this approach in
multiple hematologic malignancies, including AML,
is currently active (NCT03326921).
2.2. Limiting CAR-T cell persistence to prevent
prolonged myeloablation
Another potential approach to reduce the risk of
protracted bone marrow ablation is limiting the
long-term in vivo persistence of non-leukemic speciﬁc antigen-directed CARs. We will discuss various
approaches that are under investigation to address
this below.
One possible method is to alter the costimulatory
domain in the CAR-T cell constructs, such as using
CD28 instead of the 4-1BB signaling domain, as this
may result in shorter CAR-T cell persistence [37,38].
Another approach to limit CAR-T cell persistence is
utilizing mRNA electroporation instead of viral
transduction to incorporate CAR into T cells, as
degradation of mRNA results in CAR-T cell death. A
study by Cummins et al. using RNA CD123 CAR-T
cells in relapsed/refractory AML showed a good
safety proﬁle; however, no objective anti-tumor
response was observed. Several drawbacks, such as
poor persistence, longer manufacturing time, and
lower CAR-T cell viability, have limited the clinical
utility of this approach [39].
Incorporating a “safety switch” in CAR-T cells is a
strategy assessed in both preclinical and clinical
studies that can eliminate T cells if needed. The
HSV-thymidine kinase suicide gene has been
investigated as a safety switch that resulted in the
depletion of cells by converting a prodrug into a
toxic compound that halts DNA replication and
results in cell death [40]. Unfortunately, this
approach is not without limitations. The long latency before activation limits its utility in acute
toxicity requiring immediate termination. This
approach also makes ganciclovir unusable in a

patient population at high risk of life-threatening
viral infections [41].
More recently, an inducible caspase 9 (iCasp9M)
has been developed to co-express in CAR-T cells as
a safety switch, consisting of a modiﬁed human
caspase 9 fused to a human FK506 binding protein
(FKBP) [42]. Exposure to a small-molecule pharmaceutical results in conditional dimerization and
activation of iCasp9M that induces apoptosis of
transduced T cells both in vitro and in vivo.
Compared with other suicide gene approaches, this
system has the advantages of low potential for
immunogenicity, selective elimination of transduced T cells, and viable function in T cells overexpressing antiapoptotic molecules. In a population
of ﬁve pediatric patients who developed GVHD
after receiving CD19 CAR-T cells for r/r ALL, a
single dose of AP1903 eliminated >90% of T cells
within 30 minutes [43]. The iCasp9m suicide system
has been incorporated in the CAR construct of
several trials (NCT02992210 and 01822652) [44]. Engineering T cells to co-express a well-characterized
surface antigen that are targets for clinically
approved monoclonal antibodies is another option
for a safety switch. Examples include truncated
EGFR/cetuximab and CD20/rituximab or depleting
CAR-T cells using targetable endogenous receptors,
such as CD52 with alemtuzumab [45,46].
While suicide gene systems may be useful in
limiting toxicities from the persistence of CAR-T
cells, they may also result in an increased risk of
disease recurrence. To overcome this potential limitation, controllable CAR-T cells whose function can
be reversed is another possible strategy to limit
toxicity [47]. Tetracycline (Tet)-ON/Tet-OFF inducible CAR19-T cells responsive to tetracycline have
been developed for B cell lymphomas in vitro. These
systems can be reactivated in the setting of declining
response or relapse if within the life span of CAR-T
cells [48].
2.3. Creation of AML-speciﬁc antigens through
genetic manipulation of HSCs before allogeneic
hematopoietic cell transplantation
Kim et al. suggested a novel approach to create
AML-speciﬁc antigens by editing out the CD33 antigen from normal HSCs prior to allogeneic HCT.
Post-engraftment treatment with CD33 CAR-T cells
engineered from donor cells targeted CD33 positive
AML blasts and stem cells and spared HSCs lacking
this antigen. This would ensure normal hematopoiesis despite the persistence of CAR-T cells. This
model showed promising results in preclinical
studies [14]. Currently, a phase I/II study is in

Table 2. Ongoing clinical trials for adoptive cell therapies in AML.
Status

Location

AML type

Study type and Age
group

Intervention

Outcomes

NCT04884984

Recruiting

CLL1 þ r/r AML

Single arm, singlecenter

Anti-CLL1 CAR-T

NCT04923919

Recruiting

The First Afﬁliated
Hospital of Soochow University,
China
920th Hospital of
Joint Logistics Support Force of People's Liberation
Army of China

CLL1 þ r/r AML

Single arm
Early phase 1

Anti-CLL1 CAR-T

NCT03631576

Unknown

Fujian Medical
University, China

r/r AML

Anti- CD123/CLL1
CAR-T

NCT03114670

Unknown

Afﬁliated Hospital
to Academy of Military Medical Sciences, China

CD123þ AML
relapsed post
allogenic stem
cell transplant

Single arm, phase
2,3
Age: <70 years
Single arm, Phase 1

Primary: Treatmentrelated adverse events
Secondary: 2-year ORR,
OS, EFS, CIR
Primary: Treatmentrelated adverse effects up
to 12 months after infusion
Secondary: Up to 1 year
ORR, PFS, OS, change of
CAR copies, and CAR-T
cell counts
Primary: 1-year LFS
Secondary: TRAE at 1 year

NCT04678336

Recruiting

University of Pennsylvania, USA

r/r AML

Single group phase
1
Age: 1e29 years

Anti CD123 CAR-T

NCT03766126

Active, not
recruiting

University of Pennsylvania, USA

r/r AML

Single group phase
1
Age:  18 years

Anti CD123 CAR-T

NCT03796390

Unknown

Hebei Yanda
Ludaopei Hospital,
China

r/r AML

Single group phase
1
Age: 2e65 years

Anti CD123
CAR-T

Anti-CD123 CAR-T

Primary: Incidence of
TRAEs
Secondary: CAR-T cell
persistence in vivo, CAR-T
speciﬁc antibody level, OS
and disease response
Primary: TRAEs, CAR-Tmanufacturing feasibility
Secondary: Day 28 ORR,
reduction in peripheral
blood
and marrow blast count,
OS, PFS, DOR, need for
rescue alloSCT
Primary: Severity and frequency of adverse effects,
Percentage of
manufacturing products
that do not meet release
criteria
Secondary: OS, PFS, DOR,
need for rescue alloSCT
Primary: Tumor load
(upto
12 months)
Secondary: CAR-T cell
persistence (upto 12
months)
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Clinical trial No.

(continued on next page)
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Table 2. (continued )
Status

Location

AML type

Study type and Age
group

Intervention

Outcomes

NCT03971799

Recruiting

Center for International Blood and
Marrow Transplant
Research, USA

CD33þ r/r AML

Single arm, multicenter phase 1,2
Age: 1e35 years

Anti-CD33
CAR-T

NCT05008575

Recruiting

Xinqiao Hospital,
China

r/r AML

Anti-CD33
CAR-NK cells

NCT02944162

Unknown

Hefei Binhu Hospital, China

r/r AML

NCT01864902

Unknown

Chinese PLA General Hospital

CD33 þ r/r AML

Single group phase
1
Age: 18e70 years
Single group phase
1/2
Age: 3e80 years
Single arm, phase
2,3
Age: 5e90 years

Primary: Maximum tolerated dose, rates of
morphologic remission at
day 28
Secondary: 1 year OS, PFS,
Treatment-related
mortality
Primary: Incidence of
ORR, DLT
Secondary: PFS, ORR, OS
Primary: TRAE
Secondary: ORR

NCT05215015

Recruiting

Wuxi People's Hospital, China

r/r AML

Anti- CD33/
CLL1CAR-NK cells

NCT03896854

Unknown

CD19 þ r/r AML

NCT04351022

Recruiting

The First Afﬁliated
Hospital of Soochow University,
China
The First Afﬁliated
Hospital of Soochow University,
China

Single group early
phase 1
Age: 18e75 years
Single group phase
1,2
Age: 6e65 years

CD38þ r/r AML

Single group phase
1,2
Age: 6e65 years

Anti CD38 CAR-T

NCT04762485

Recruiting

The First Afﬁliated
Hospital of Soochow University,
China

r/r CD7þ Acute
leukemia

Single group phase
1/2
Age: 12e65 years

Anti CD7 CAR-T

NCT04692948

Recruiting

r/r AML

Recruiting

Single group
Age: 18-70
Single group phase
1
Age: 10e75 years

Anti- CD276 CAR-T

NCT05247957

Anhui provincial
hospital, China
Hebei Yanda Lu
Daopei Hospital,
China

r/r AML

Anti-CD33
CAR-NK cells
Anti CD33 CAR-T

Anti CD19 CAR-T

NKG2DL-speciﬁc
CAR-NK cells

Primary: TRAEs until
week
24
Secondary: Anti-leukemic
Responses to CAR-T upto
24 weeks, in vivo existence
of CAR-T at 1 year
Primary: Incidence of DLT
Secondary: OS, ORR,
DOR, MRD
Primary: Adverse events
over 12 months

Primary: Number of
adverse events in 12
months
Secondary: 2-year ORR,
EFS and CIR
Primary: Number of
adverse events
Secondary: ORR, CIR,
persistence of CAR-T cells
in vivo
Primary: 3-month ORR
Primary: Incidence of
DLT,
Maximal tolerable dose
Secondary: LFS

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:159e167

Clinical trial No.

Primary: Number of
adverse events in 12
months post infusion
Secondary: 2- year ORR,
EFS, CIR
Anti-FLT3 CAR-T
FLT3 þ r/r AML
Recruiting
NCT05023707

ORR: Objective response rate; OS: Overall survival; EFS: Event-free survival; TRAE: Treatment-related adverse effects. CIR: Cumulative incidence of relapse; LFS: Leukemia-free
survival; DOR: Duration of response; alloSCT: Allogenic stem cell transplant; DLT: Dose-limiting toxicity.

Primary: TRAE
Not yet
recruiting
NCT05092451

M.D. Anderson
Cancer Center,
U.S.A.
The First Afﬁliated
Hospital of Soochow University,
China

CD70 þ r/r AML

Single group phase
1/2
Age: 18e80 years
Single arm phase 1,
phase 2

CAR.70/IL15-transduced
CB-NK cells
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progress evaluating the safety of VOR33, an allogeneic CRISPR/Cas9 genome-edited HSC lacking
CD33 followed by gemtuzumab ozogamicin, in
AML patients at high risk for relapse after HCT
[NCT04849910]. Editing other antigens, such as
CD123 and CLL-1, from HSCs prior to transplant is
also being studied. A preclinical evaluation of
engineered HSPCs with ablated CD123 or CLL-1
proteins obtained from healthy donors’ peripheral
blood showed successful functional hematopoiesis
resistant to CD123 or CLL-1 targeted therapies,
providing a next-generation HCT option that would
facilitate safe and effective use of antigen-directed
immunotherapy treatments for AML [49].
2.4. Mitigating downregulation of target antigens
and antigen escape
Similar to the irreversible loss of CD19 as a
mechanism for relapse after CAR-T cell therapy in
relapsed/refractory B-ALL [50], there is a concern
that downregulation of target antigen or antigen
escape could reduce the efﬁcacy of CAR-T/NK cell
therapies for AML. Several potential approaches to
overcome this issue are under investigation,
including creating adoptive cell therapy against
multiple antigens and methods to upregulate the
target antigens.
Targeting a single antigen may be insufﬁcient for
CAR-T cell treatment, and creating tandem CARs
that recognize two epitopes can circumvent this
concern. A preclinical study assessing the efﬁcacy of
CD123b-CD33b CCAR composed of anti-CD123 and
anti-CD33 CAR units showed ablation of leukemic
cells expressing CD123, CD33b, or both ex vivo in
AML cells and in vivo in xenograft models [15].
Similarly, CLL1-CD33 compound CAR-T cells have
shown promise in eliminating AML cells in preclinical studies and a phase I dose escalation trial
[51]. Clinical trials assessing the utility of compound
CAR-T cells are currently ongoing.
Another potential method to overcome AML
target antigen downregulation is using therapies
that upregulate these antigens. A study by Li et al.
showed that decitabine increases CD19 expression
in lymphoma cells, and cells pretreated with decitabine responded better to CAR-T cells targeting
CD19. This method succeeded in two patients with
relapsed/refractory B cell lymphoma who achieved
complete remission [52]. This method is yet to be
applied to AML CARs. Similarly, a study by Khawanky et al. showed that CD123 expression increases in leukemia cells on exposure to
hypomethylating agents, such as azacytidine, in
AML xenograft models [53]. Another agent known
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to increase the expression of leukemia antigens is
all-trans-retinoic acid (ATRA). It increases the
expression of CD38 in AML cells, and a study by
Yoshida et al. assessing the enhancement of CD38
expression of AML cells using ATRA showed
increased efﬁcacy of anti-CD38-CAR in vitro, suggesting the potential utility of this modality [54].

3. Clinical trials using adoptive cellular
therapy
Table 2 summarizes the currently active clinical
trials using experimental CAR-T and CAR-NK
therapies in treating AML. The target antigens
include CD33, CD38, CLL1, FLT3, CD123, CD19,
CD70, and CD276. Most of these are in phase 1e2,
with the primary aim of identifying treatmentrelated toxicities.

4. Conclusion
Adoptive cellular therapy in AML continues to
face several challenges, especially treatment-related
toxicity. However, with several strategies in clinical
trials, there is certainly a promise of its potential for
AML treatment being realized soon.
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